‘
Joshua Kriger
Founder, CEO
Founder, CEO
Clinical trial statistician and statistical expert, with a range of leadership experience across the healthcare industry and government agencies
Formerly led the global analytics group for ICAP’s Population HIV Impact Assessment (PHIA), the largest biomarker assessment ever conducted by the CDC
Formerly led the global analytics group for ICAP’s Population HIV Impact Assessment (PHIA), the largest biomarker assessment ever conducted by the CDC
Joshua Kriger
Founder, CEO
Founder, CEO
Clinical trial statistician and statistical expert, with a range of leadership experience across the healthcare industry and government agencies
Formerly led the global analytics group for ICAP’s Population HIV Impact Assessment (PHIA), the largest biomarker assessment ever conducted by the CDC
Formerly led the global analytics group for ICAP’s Population HIV Impact Assessment (PHIA), the largest biomarker assessment ever conducted by the CDC
Lauren Williams
Director Of Data Science
Director Of Data Science
Chief architect for product selection model within proprietary technology platform
Leads initiatives in machine learning optimization, risk reduction, scientific support and strategic assessments
Leads initiatives in machine learning optimization, risk reduction, scientific support and strategic assessments
Lauren Williams
Director Of Data Science
Director Of Data Science
Chief architect for product selection model within proprietary technology platform
Leads initiatives in machine learning optimization, risk reduction, scientific support and strategic assessments
Leads initiatives in machine learning optimization, risk reduction, scientific support and strategic assessments
Robert Goldfarb
Lead Counsel
Lead Counsel
Over 20 years of experience with in the generic pharmaceutical industry
Contract expert with CDMOs, supply chain and API sources
Formerly the General Counsel at Andrx Corp and led the $1.9B sale to Watson Pharmaceuticals
Contract expert with CDMOs, supply chain and API sources
Formerly the General Counsel at Andrx Corp and led the $1.9B sale to Watson Pharmaceuticals
Robert Goldfarb
Lead Counsel
Lead Counsel
Over 20 years of experience with in the generic pharmaceutical industry
Contract expert with CDMOs, supply chain and API sources
Formerly the General Counsel at Andrx Corp and led the $1.9B sale to Watson Pharmaceuticals
Contract expert with CDMOs, supply chain and API sources
Formerly the General Counsel at Andrx Corp and led the $1.9B sale to Watson Pharmaceuticals
Les Funtelyder
Executive Board Member
Executive Board Member
Internationally prominent healthcare investor with a track record of significant positive returns across a range of healthcare industries
Widely quoted in media for his perspectives on the healthcare sector
Widely quoted in media for his perspectives on the healthcare sector
Les Funtelyder
Executive Board Member
Executive Board Member
Internationally prominent healthcare investor with a track record of significant positive returns across a range of healthcare industries
Widely quoted in media for his perspectives on the healthcare sector
Widely quoted in media for his perspectives on the healthcare sector
David Rosen
Advisor
Advisor
Formerly a FDA officer for 14 years and served as the division chief of generic drugs review support branch and as regulatory counsel
In 1979, Mr. Rosen led the creation of the FDA Orange Book
Mr. Rosen was also involved in the writing and implementation of the Hatch-Waxman Act
In 1979, Mr. Rosen led the creation of the FDA Orange Book
Mr. Rosen was also involved in the writing and implementation of the Hatch-Waxman Act
David Rosen
Advisor
Advisor
Formerly a FDA officer for 14 years and served as the division chief of generic drugs review support branch and as regulatory counsel
In 1979, Mr. Rosen led the creation of the FDA Orange Book
Mr. Rosen was also involved in the writing and implementation of the Hatch-Waxman Act
In 1979, Mr. Rosen led the creation of the FDA Orange Book
Mr. Rosen was also involved in the writing and implementation of the Hatch-Waxman Act
Lewis Tepper
Advisor
Advisor
Over 20 years of operation and investing experience of early stage companies in the medical device, pharmaceutical and healthcare IT sectors
Formerly the COO, General Counsel and employee #3 of DAVA Pharmaceuticals, which was acquired by Endo International in 2014 for $575M
Formerly the COO, General Counsel and employee #3 of DAVA Pharmaceuticals, which was acquired by Endo International in 2014 for $575M
Lewis Tepper
Advisor
Advisor
Over 20 years of operation and investing experience of early stage companies in the medical device, pharmaceutical and healthcare IT sectors
Formerly the COO, General Counsel and employee #3 of DAVA Pharmaceuticals, which was acquired by Endo International in 2014 for $575M
Formerly the COO, General Counsel and employee #3 of DAVA Pharmaceuticals, which was acquired by Endo International in 2014 for $575M